Cargando…

Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine

BACKGROUND: In non-human primates (NHPs) and humans, partial protection from HIV/SIV infection or suppression of replication is achievable by Env-binding antibodies and Gag-specific CD8+ T-cells targeting protective epitopes. Unfortunately, such T-cell responses are frequently dominated by responses...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwerdtfeger, Melanie, Andersson, Anne-Marie Carola, Neukirch, Lasse, Holst, Peter Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534914/
https://www.ncbi.nlm.nih.gov/pubmed/31126293
http://dx.doi.org/10.1186/s12967-019-1924-1
_version_ 1783421509018058752
author Schwerdtfeger, Melanie
Andersson, Anne-Marie Carola
Neukirch, Lasse
Holst, Peter Johannes
author_facet Schwerdtfeger, Melanie
Andersson, Anne-Marie Carola
Neukirch, Lasse
Holst, Peter Johannes
author_sort Schwerdtfeger, Melanie
collection PubMed
description BACKGROUND: In non-human primates (NHPs) and humans, partial protection from HIV/SIV infection or suppression of replication is achievable by Env-binding antibodies and Gag-specific CD8+ T-cells targeting protective epitopes. Unfortunately, such T-cell responses are frequently dominated by responses to non-protective, variable epitopes. In this study we attempt to combine three independent approaches, each developed to prevent immunodominance of non-protective epitopes. These approaches were (1) vaccines consisting exclusively of putatively protective p24 Gag highly conserved elements (CEs), (2) vaccines using solely subdominant antigens which were acutely protective in a recent NHP trial, and (3) virus-encoded virus-like particle vaccines (virus-like vaccines/VLVs) using heterologous Env and Gag sequences to enable selection of broadly cross-reactive responses and to avoid immunodominance of non-conserved sequences in prime-boost regimens as previously observed. METHODS: We vaccinated outbred CD1 mice with HIV-1 clade B Gag/Env encoded in an adenoviral prime and SIVmac239 Gag/Env in an MVA boost. We combined this completely heterologous immunization regimen and the homologous SIVmac239 Gag/Env immunization regimen with an additional prime encoding SIV CEs and accessory antigens Rev, Vif and Vpr (Ad-Ii-SIVCErvv). T-cell responses were analyzed by intracellular cytokine staining of splenocytes and antibody responses by trimer-specific ELISA, avidity and isotype-specific ELISA. RESULTS: Env dominance could be avoided successfully in the completely heterologous prime-boost regimen, but Env immunodominance reappeared when Ad-Ii-SIVCErvv was added to the prime. This regimen did however still induce more cross-reactive Gag-specific CD8+ T-cells and Env-specific antibodies. Including Ad-Ii-SIVCErvv in the homologous prime-boost not only elicited accessory antigen-specific CD8+ memory T-cells, but also significantly increased the ratio of Gag- to Env-specific CD8+ T-cells. The CD4+ T-cell response shifted away from structural antigens previously associated with infection-enhancement. CONCLUSION: The homologous Gag/Env prime-boost with Ad-Ii-SIVCErvv prime combined acutely protective CD8+ T-cell responses to subdominant antigens and Env-binding antibodies with chronically protective Gag-specific CD8+ T-cells in outbred mice. This vaccine regimen should be tested in an NHP efficacy trial. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12967-019-1924-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6534914
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65349142019-05-30 Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine Schwerdtfeger, Melanie Andersson, Anne-Marie Carola Neukirch, Lasse Holst, Peter Johannes J Transl Med Research BACKGROUND: In non-human primates (NHPs) and humans, partial protection from HIV/SIV infection or suppression of replication is achievable by Env-binding antibodies and Gag-specific CD8+ T-cells targeting protective epitopes. Unfortunately, such T-cell responses are frequently dominated by responses to non-protective, variable epitopes. In this study we attempt to combine three independent approaches, each developed to prevent immunodominance of non-protective epitopes. These approaches were (1) vaccines consisting exclusively of putatively protective p24 Gag highly conserved elements (CEs), (2) vaccines using solely subdominant antigens which were acutely protective in a recent NHP trial, and (3) virus-encoded virus-like particle vaccines (virus-like vaccines/VLVs) using heterologous Env and Gag sequences to enable selection of broadly cross-reactive responses and to avoid immunodominance of non-conserved sequences in prime-boost regimens as previously observed. METHODS: We vaccinated outbred CD1 mice with HIV-1 clade B Gag/Env encoded in an adenoviral prime and SIVmac239 Gag/Env in an MVA boost. We combined this completely heterologous immunization regimen and the homologous SIVmac239 Gag/Env immunization regimen with an additional prime encoding SIV CEs and accessory antigens Rev, Vif and Vpr (Ad-Ii-SIVCErvv). T-cell responses were analyzed by intracellular cytokine staining of splenocytes and antibody responses by trimer-specific ELISA, avidity and isotype-specific ELISA. RESULTS: Env dominance could be avoided successfully in the completely heterologous prime-boost regimen, but Env immunodominance reappeared when Ad-Ii-SIVCErvv was added to the prime. This regimen did however still induce more cross-reactive Gag-specific CD8+ T-cells and Env-specific antibodies. Including Ad-Ii-SIVCErvv in the homologous prime-boost not only elicited accessory antigen-specific CD8+ memory T-cells, but also significantly increased the ratio of Gag- to Env-specific CD8+ T-cells. The CD4+ T-cell response shifted away from structural antigens previously associated with infection-enhancement. CONCLUSION: The homologous Gag/Env prime-boost with Ad-Ii-SIVCErvv prime combined acutely protective CD8+ T-cell responses to subdominant antigens and Env-binding antibodies with chronically protective Gag-specific CD8+ T-cells in outbred mice. This vaccine regimen should be tested in an NHP efficacy trial. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12967-019-1924-1) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-24 /pmc/articles/PMC6534914/ /pubmed/31126293 http://dx.doi.org/10.1186/s12967-019-1924-1 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Schwerdtfeger, Melanie
Andersson, Anne-Marie Carola
Neukirch, Lasse
Holst, Peter Johannes
Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine
title Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine
title_full Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine
title_fullStr Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine
title_full_unstemmed Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine
title_short Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine
title_sort virus-like vaccines against hiv/siv synergize with a subdominant antigen t cell vaccine
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534914/
https://www.ncbi.nlm.nih.gov/pubmed/31126293
http://dx.doi.org/10.1186/s12967-019-1924-1
work_keys_str_mv AT schwerdtfegermelanie viruslikevaccinesagainsthivsivsynergizewithasubdominantantigentcellvaccine
AT anderssonannemariecarola viruslikevaccinesagainsthivsivsynergizewithasubdominantantigentcellvaccine
AT neukirchlasse viruslikevaccinesagainsthivsivsynergizewithasubdominantantigentcellvaccine
AT holstpeterjohannes viruslikevaccinesagainsthivsivsynergizewithasubdominantantigentcellvaccine